Market Overview

UPDATE: Ladenburg Thalmann Upgrades AMAG Pharmaceuticals to Buy

Related AMAG
Why AMAG Pharmaceuticals (AMAG) Could Be Positioned for a Slump - Tale of the Tape
AMAG Pharma Announces Publication of Data from Trial of MuGard in the Journal Cancer

Ladenburg Thalmann has published a research report on AMAG Pharmaceuticals (NASDAQ: AMAG) and has upgraded the company from Neutral to Buy based on valuation.

In the report, Ladenburg Thalmann writes, "In essence, despite our view that Feraheme does not represent a great business for AMAG, we believe the Company is undervalued at these levels. Our valuation method which renders a 12 month PT of $15.00 (Table on next page) does give some credit to the potential impact of label expansion but takes a conservative approach to valuing cash (we use cash by YE-2013) and uses conservative revenue multiples (2.0x)."

Ladenburg Thalmann has established a $15 price target on AMAG Pharmaceuticals, which is currently trading up $0.62 from yesterday's $12.54 closing price.

Latest Ratings for AMAG

DateFirmActionFromTo
Aug 2014FBR CapitalInitiates Coverage onMarket Perform
Jan 2014JefferiesUpgradesUnderperformHold
Jan 2014Ladenburg ThalmannDowngradesBuyNeutral

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: Ladenburg ThalmannAnalyst Color Upgrades Price Target Analyst Ratings

 

Related Articles (AMAG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters